Follow The Money VIP Research

FOLLOW THE MONEY: Who's Funding the Psychedelic Boom

Heal with Hillary — VIP Research Series, Vol. 01

You already know psilocybin works. You've seen the clinical data, watched the stigma start to crack. What you probably haven't seen is who's positioned to profit from it, and how far they've already gone to make sure they do.

This isn't another wellness explainer. It's an investigative briefing: 16 pages tracing the actual capital behind psilocybin's rise, from a 2020 patent that tried to claim ownership over a therapist holding your hand, to the index funds quietly sitting on the cap table of the company racing hardest toward FDA approval.

What's inside:

• The 6,000-year-old, healer-led, zero-cost tradition this all started from
• Why "no accepted medical use" never actually held up under the Schedule I standard it was judged by
• A side-by-side of psilocybin's 55-year ban against an SSRI that reached millions of patients for 17 years before its risks were fully disclosed
• The documented trial data behind psilocybin's results treating nicotine and alcohol addiction
• Peter Thiel's investment trail, and the 2020 patent filing that tried to own the room itself
• What BlackRock and Vanguard's stake in Eli Lilly actually means (and doesn't)
• The core tension underneath all of it: patented, profit-driven therapy vs. a medicine that used to be free

Every claim is sourced, SEC filings, patents, peer-reviewed research, and on-the-record reporting, cited throughout. But this isn't just a stack of facts. Throughout the guide, I ask the questions most people are too polite, or too afraid, to ask out loud, and I follow them with my own opinion, clearly labeled as mine and never dressed up as fact. That's the whole format: what's documented, and what I think it means. You get to decide where you land.

Founding reader price: $25. This is Vol. 01. Future volumes in this series will be priced higher once there's a full library behind them, get in now.

This is educational content, not medical advice. It contains no dosing, sourcing, or facilitation guidance.